ArticleNPJ digital medicine2025
Fibricheck detection capabilities for atrial fibrillation (FDA-AF): a multicenter validation study.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High-probability heart failure with preserved ejection fraction phenotype in atrial fibrillation patients undergoing ablation: insights from RECAP.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Heterogeneity in endpoints, monitoring methods and blanking periods in clinical trials of atrial fibrillation ablation: a systematic review and meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Validation and implementation of ambulatory obstructive sleep apnea polygraphy screening combined with wearable semi-continuous heart rhythm monitoring in patients with atrial fibrillation: a validation and a pilot study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. FibriCheck is a medical analysis platform that uses an end-to-end algorithm to detect AF based on photoplethysmography signals recorded on consumer smartphones. The study aimed to validate FibriCheck in a multicenter, multinational cohort of 236 subjects across ten popular smartphone devices. The 12-lead electrocardiogram was used as the reference diagnosis. FibriCheck demonstrated high overall performance: accuracy 98.5% (95% CI: 98.0-99.0%); sensitivity 96.3% (95% CI: 94.4-97.7%); specificity 99.3% (95% CI: 98.8-99.7%). Performance was not affected by smartphone device or comorbid heart failure, vascular disease, hypertension, diabetes, or stroke. Sensitivity was reduced in individuals with darker skin tones and higher BMIs, but this was mitigated by technician verification. The study confirms the high accuracy, sensitivity, and specificity of the FibriCheck algorithm in detecting AF across various smartphone models and clinical subgroups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.